Emcure Pharmaceuticals reported a 22.8% revenue increase to ₹2,580 crore for the June quarter. The company is sharpening its focus on biosimilars and complex generics while fully acquiring its subsidiary, Gennova.
Emcure Pharmaceuticals posted strong financial results for the quarter ending June 30, 2026, driven by high demand in international markets. The company reported a revenue of ₹2,580 crore, marking a 22.8% increase compared to the same period last year. Profit after tax saw a significant rise of 36.2%, reaching ₹292.5 crore. The company's international operations served as the main growth engine, expanding by 34.2% and now contributing 57.6% to the total revenue. Specifically, growth was strong in Europe, which grew by 32.8%, and Canada, which saw a 24.6% increase.
In a major strategic shift, Emcure has moved to simplify its corporate structure by acquiring the remaining 12.05% stake in its subsidiary, Gennova Biopharmaceuticals, for ₹231.87 crore. This gives Emcure 100% control over the unit. Simultaneously, the company has decided to exit the mRNA vaccine business, selling it to Immunoscript Life Science for ₹139.5 crore. Management indicated that this decision was taken to better allocate resources toward high-potential areas like biosimilars and complex generics. This change allows the company to concentrate its research and manufacturing capabilities on products with a more predictable growth path.
On the regulatory front, the company received a positive update as its Sanand facility in Gujarat was granted a 'Voluntary Action Indicated' (VAI) status by the USFDA. This is a favorable development that typically signifies that regulatory inspectors found some issues but decided that voluntary action is sufficient, avoiding more serious enforcement measures. This status helps ensure smoother export operations, which is important given the company's heavy reliance on international markets.
Despite the positive results, there are specific factors for investors to monitor. The acquisition of the remaining stake in Gennova and other operational needs are expected to push net debt to approximately ₹1,450 crore in the short term. While the company is performing well in its core areas, investors should note that international business now accounts for more than half of total revenue, making the company susceptible to global regulatory shifts and currency fluctuations. Furthermore, the global pharmaceutical market remains highly competitive, and the company will need to maintain its focus on product execution to sustain the current growth momentum. Moving forward, the market will likely track the integration of the fully-owned subsidiary and the company’s ability to manage its debt levels while executing its expansion plans in biosimilars and HIV therapies.